SAC Capital Advisors’s AstraZeneca AZN Stock Holding History

SAC Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-367,034	Closed	-$23.8M	–	112
2014 Q1	$23.8M	Sell	367,034 -166,228	-31%	-$10.7M	0.12%	229
2013 Q4	$31.7M	Buy	533,262 +1,149	+0.2%	+$62.4K	0.18%	140
2013 Q3	$27.6M	Buy	532,113 +520,147	+4,347%	+$26.1M	0.15%	177
2013 Q2	$566K	Buy	+11,966	New	+$609K	﹤0.01%	1067

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SAC Capital Advisors's AZN Position: Q2 2014 in Review

SAC Capital Advisors sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 367,034 shares — an estimated $23.8M sold.

SAC Capital Advisors first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $31.7M in Q4 2013. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

SAC Capital Advisors reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 367,034 AstraZeneca shares in Q2 2014, an estimated $23.8M.
SAC Capital Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's AstraZeneca position peaked at $31.7M in Q4 2013.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.